Generated by AI
Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion. Its portfolio also includes additional preclinical programs targeting fibrosis-related pathways and cystic fibrosis. Rein Therapeutics develops peptide-based and protein-based therapeutics designed to address serious diseases with limited treatment options, making it a specialized player in respiratory and fibrotic medicine. Headquartered in Austin, Texas, Rein Therapeutics serves the biopharmaceutical market through research, clinical development, and product advancement for highly targeted rare-disease applications.
Website12407 N. Mopac Expy.
Austin, TX, 78758
United States
The latest articles about RNTX.
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s
Summary of Nov 16's posts. Generated by AI.
No summary yet.
Summary of Oct 21's posts. Generated by AI.
No summary yet.
Summary of Oct 21's posts. Generated by AI.
Investors talking about RNTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.